Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter. Sales of heart ...
Sales of Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the drugmaker lifted profit guidance for a third straight quarter.